When was GIOSTAR founded?

GIOSTAR was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is GIOSTAR located?

GIOSTAR is headquartered in San Diego, United States. It is registered at 6/A, Harihar Society, Opp. Gujarat Vidhyapith, Ashram Road, Usmanpura, Ahmedabad, Gujarat, India, 380013.

How many employees does GIOSTAR have?

As of May 31, 2026, the latest employee count at GIOSTAR is 70.

Is GIOSTAR a funded company?

GIOSTAR is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Apr 30, 2013.

When was the latest funding round of GIOSTAR?

GIOSTAR's latest funding was a $***** Grant (prize money) round on Apr 30, 2013, with participation from 1 investor.

Where does GIOSTAR rank among its competitors?

GIOSTAR ranks 1173rd amongst 2434 active competitors, of which 628 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of GIOSTAR?

GIOSTAR's top competitors include Alnylam, Spark Therapeutics and Synthego. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

GIOSTAR - 2026 Company Profile, Team, Funding & Competitors

GIOSTAR is a funded company based in San Diego (United States), founded in 2012 by Deven Patel and Siddharth Bhavsar. It operates as a Developer of stem cell-based therapy for degenerative and genetic diseases. GIOSTAR has raised an undisclosed amount in funding. The company has 2434 active competitors, including 628 funded and 451 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Synthego.

Company Details

Developer of stem cell-based therapy for degenerative and genetic diseases. It has developed a technique for the extraction of stem cells from a human body and uses them for autologous and allogeneic stem cells transplant. It claims that it has the ability to treat several immunological diseases and blood-related diseases that include diabetes type I and type II, lupus, multiple sclerosis, Crohn's disease, vasculitis, scleroderma, myasthenia gravis, sickle cell anemia, leukemia, lymphoma, thalassemia, and developing the therapies for Alzheimer’s, Autism, Anti-Aging Treatments, Parkinson’s disease, Cancer, Heart and Retinal Degeneration and Spinal Muscular Atrophy (SMA).

Website: www.giostar.com/
Social
Email ID: *****@giostar.com
Phone Number: +1 **********
Registered Address: 6/A, Harihar Society, Opp. Gujarat Vidhyapith, Ashram Road, Usmanpura, Ahmedabad, Gujarat, India, 380013

Key Metrics

Founded Year

2012

Location

San Diego, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Apr 30, 2013, $*****

Investors

Grand Challenges Canada

Ranked

1173^rd among 2434 active competitors

Employee Count

70 as on May 31, 2026

Similar Companies

Alnylam & 3266 more

View GIOSTAR's full profile

GIOSTAR is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
GIOSTAR RESEARCH PRIVATE LIMITED CIN: U73100GJ2009PTC058156 , India, Active	Sep 22, 2009	0 - ₹10 Cr (As on Mar 31, 2025)	-
GIOSTAR REGEN PRIVATE LIMITED CIN: U73100GJ2020PTC118853 , India, Active	Dec 15, 2020	0 - ₹10 Cr (As on Mar 31, 2025)	-
CANCEND RESEARCH PRIVATE LIMITED CIN: U73200GJ2020PTC118883 , India, Active	Dec 16, 2020	0 - ₹10 Cr (As on Mar 31, 2024)	-

GIOSTAR has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Apr 30, 2013 for $*****. 1 investor participated in its latest round. GIOSTAR has 1 institutional investor.

Here is the list of recent funding rounds of GIOSTAR:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 30, 2013	6259725	Grant (prize money)	1390763	6723747	7358724	1186992

Access funding benchmarks and valuations. Sign up today!

View details of GIOSTAR's funding rounds and investors

The founders of GIOSTAR are Deven Patel and Siddharth Bhavsar.

Here are the details of GIOSTAR's key team members:

Deven Patel: Co-Founder & CEO of GIOSTAR and founder of 1 other company.
Contact Info: 2 email addresses
Siddharth Bhavsar: Co-Founder & CFO of GIOSTAR and founder of 1 other company.
Contact Info: 1 email address

View details of GIOSTAR's Founder profiles and Board Members

GIOSTAR's employee count trend

GIOSTAR has 70 employees as of May 26. Here is GIOSTAR's employee count trend over the years:

Uncover GIOSTAR's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GIOSTAR include Alnylam, Spark Therapeutics and Synthego. Here is the list of Top 10 competitors of GIOSTAR, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
4th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
5th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Xontogeny & 7 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Adage Capital Management, F-Prime Capital ... & 10 others	69/100
9th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
10th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
1173rd	GIOSTAR 2012, San Diego (United States), Funding Raised	Developer of stem cell-based therapy for degenerative and genetic diseases	-	Grand Challenges Canada	29/100